Background—We aimed to determine the incidence, predictors, clinical characteristics, management, and outcomes of infective endocarditis (IE) after transcatheter aortic valve implantation (TAVI). Methods and Results—This multicenter registry included 53 patients (mean age, 79±8 years; men, 57%) who

Background— We aimed to determine the incidence, predictors, clinical characteristics, management, and outcomes of infective endocarditis (IE) after transcatheter aortic valve implantation (TAVI). Methods and Results— This multicenter registry included 53 patients (mean age, 79±8 years; men, 57%) who suffered IE after TAVI of 7944 patients after a mean follow-up of 1.1±1.2 years (incidence, 0.67%, 0.50% within the first year after TAVI). Mean time from TAVI was 6 months (interquartile range, 1–14 months). Orotracheal intubation (hazard ratio, 3.87; 95% confidence interval, 1.55–9.64; P=0.004) and the self-expandable CoreValve system (hazard ratio, 3.12; 95% confidence interval, 1.37–7.14; P=0.007) were associated with IE (multivariate analysis including 3067 patients with individual data). The most frequent causal microorganisms were coagulase-negative staphylococci (24%), followed by Staphylococcus aureus (21%) and enterococci (21%). Vegetations were present in 77% of patients (transcatheter valve leaflets, 39%; stent frame, 17%; mitral valve, 21%). At least 1 complication of IE occurred in 87% of patients (heart failure in 68%). However, only 11% of patients underwent valve intervention (valve explantation and valve-in-valve procedure in 4 and 2 patients, respectively). The mortality rate in hospital was 47.2% and increased to 66% at the 1-year follow-up. IE complications such as heart failure (P=0.037) and septic shock (P=0.002) were associated with increased in-hospital mortality. Conclusions— The incidence of IE at 1 year after TAVI was 0.50%, and the risk increased with the use of orotracheal intubation and a self-expandable valve system. Staphylococci and enterococci were the most common agents. Although most patients presented at least 1 complication of IE, valve intervention was performed in a minority of patients, and nearly half of the patients died during the hospitalization period.

[1]  J. Pericàs,et al.  Letter by Pericas et al Regarding Article, "Infective Endocarditis After Transcatheter Aortic Valve Implantation: Results From a Large Multicenter Registry". , 2015, Circulation.

[2]  J. Miro,et al.  Infective endocarditis in patients with an implanted transcatheter aortic valve: Clinical characteristics and outcome of a new entity. , 2015, The Journal of infection.

[3]  J. Rodés‐Cabau,et al.  Prosthetic valve endocarditis after transcatheter valve replacement: a systematic review. , 2015, JACC. Cardiovascular interventions.

[4]  Joshua D. Hartzell,et al.  Multimodality imaging of multivalvular endocarditis after transcatheter aortic valve replacement. , 2015, Journal of cardiovascular computed tomography.

[5]  O. Alfieri,et al.  TAVR-associated prosthetic valve infective endocarditis: results of a large, multicenter registry. , 2014, Journal of the American College of Cardiology.

[6]  A. Mügge,et al.  Three-year outcomes after transcatheter aortic valve implantation with the CoreValve prosthesis. , 2014, The American journal of cardiology.

[7]  P. Pibarot,et al.  Significant mitral regurgitation left untreated at the time of aortic valve replacement: a comprehensive review of a frequent entity in the transcatheter aortic valve replacement era. , 2014, Journal of the American College of Cardiology.

[8]  F. Mohr,et al.  Surgery for infective endocarditis complicated by cerebral embolism: a consecutive series of 375 patients. , 2014, The Journal of thoracic and cardiovascular surgery.

[9]  A. Steinvil,et al.  Frequency, pattern, and cause of fever following transfemoral transcatheter aortic valve implantation. , 2014, The American journal of cardiology.

[10]  M. Hannan,et al.  In-hospital and 1-year mortality in patients undergoing early surgery for prosthetic valve endocarditis. , 2013, JAMA internal medicine.

[11]  M. Nonaka,et al.  Long-term clinical outcomes and predictors of survival after prosthetic valve endocarditis surgery. , 2013, The Journal of heart valve disease.

[12]  D. Raoult,et al.  Positron emission tomography/computed tomography for diagnosis of prosthetic valve endocarditis: increased valvular 18F-fluorodeoxyglucose uptake as a novel major criterion. , 2013, Journal of the American College of Cardiology.

[13]  J. A. Román,et al.  Importancia clínica de la insuficiencia cardiaca congestiva en la endocarditis protésica. Estudio multicéntrico de 257 pacientes , 2013 .

[14]  Jacobo A Silva,et al.  Clinical significance of congestive heart failure in prosthetic valve endocarditis. A multicenter study with 257 patients. , 2013, Revista espanola de cardiologia.

[15]  G. Hasenfuss,et al.  Prosthetic valve endocarditis after transcatheter aortic valve implantation: the incidence in a single-centre cohort and reflections on clinical, echocardiographic and prognostic features. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[16]  B. Hoen,et al.  Clinical practice. Infective endocarditis. , 2013, The New England journal of medicine.

[17]  D. Raoult,et al.  Imaging investigations in infective endocarditis: current approach and perspectives. , 2013, Archives of cardiovascular diseases.

[18]  M. Mack,et al.  Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. , 2012, The Journal of thoracic and cardiovascular surgery.

[19]  R. Kornowski,et al.  Infective Endocarditis in the Transcatheter Aortic Valve Replacement Era: Comprehensive Review of a Rare Complication , 2012, Clinical cardiology.

[20]  M. Mack,et al.  Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. , 2012, Journal of the American College of Cardiology.

[21]  V. Falk,et al.  Assessment of inflammatory response to transfemoral transcatheter aortic valve implantation compared to transapical and surgical procedures: a pilot study. , 2012, The Journal of invasive cardiology.

[22]  Susheel Kodali,et al.  Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. , 2012, The New England journal of medicine.

[23]  Scott Lim,et al.  Two-year outcomes after transcatheter or surgical aortic-valve replacement. , 2012, The New England journal of medicine.

[24]  Josep Rodés-Cabau,et al.  Transcatheter aortic valve implantation: current and future approaches , 2012, Nature Reviews Cardiology.

[25]  Antonio Colombo,et al.  One-Year Outcomes of Cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry: The European Registry of Transcatheter Aortic Valve Implantation Using the Edwards SAPIEN Valve , 2011, Circulation.

[26]  Thomas Walther,et al.  Crimping may affect the durability of transcatheter valves: an experimental analysis. , 2011, The Annals of thoracic surgery.

[27]  Stuart J Pocock,et al.  Transcatheter versus surgical aortic-valve replacement in high-risk patients. , 2011, The New England journal of medicine.

[28]  D. Paterson,et al.  Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity , 2011, Internal medicine journal.

[29]  J. Loeffler,et al.  Clinical experience with daptomycin in Europe: the first 2.5 years , 2011, The Journal of antimicrobial chemotherapy.

[30]  L. Kritharides,et al.  Health care exposure and age in infective endocarditis: results of a contemporary population-based profile of 1536 patients in Australia. , 2010, European heart journal.

[31]  A. Kamarulzaman International Collaboration on Endocarditis Prospective Cohort Study , 2008 .

[32]  P. Diz,et al.  The incidence of bacteraemia associated with tracheal intubation , 2008, Anaesthesia.

[33]  M. F. Fernández Guerrero,et al.  Enterococcal Endocarditis on Native and Prosthetic Valves: A Review of Clinical and Prognostic Factors With Emphasis on Hospital-Acquired Infections as a Major Determinant of Outcome , 2007, Medicine.

[34]  Francisco Fernández-Avilés,et al.  Prognostic stratification of patients with left-sided endocarditis determined at admission. , 2007, The American journal of medicine.

[35]  Patricia Muñoz,et al.  Contemporary clinical profile and outcome of prosthetic valve endocarditis. , 2007, JAMA.

[36]  Piet Claus,et al.  Infective endocarditis: changing epidemiology and predictors of 6-month mortality: a prospective cohort study. , 2006, European heart journal.

[37]  Patricia Muñoz,et al.  Periannular complications in infective endocarditis involving prosthetic aortic valves. , 2006, The American journal of cardiology.

[38]  J. Butany,et al.  Pathology of infectious and inflammatory diseases in prosthetic heart valves. , 2006, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[39]  Vance G Fowler,et al.  Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. , 2006, The New England journal of medicine.

[40]  Gilbert Habib,et al.  Risk of Embolism and Death in Infective Endocarditis: Prognostic Value of Echocardiography: A Prospective Multicenter Study , 2005, Circulation.

[41]  G. Baron,et al.  Infective endocarditis in Europe: lessons from the Euro heart survey , 2003, Heart.

[42]  Joan Buenconsejo,et al.  Complicated left-sided native valve endocarditis in adults: risk classification for mortality. , 2003, JAMA.

[43]  Daniel J Sexton,et al.  Health CareAssociated Bloodstream Infections in Adults: A Reason To Change the Accepted Definition of Community-Acquired Infections , 2002, Annals of Internal Medicine.

[44]  Bruno Hoen,et al.  Changing profile of infective endocarditis: results of a 1-year survey in France. , 2002, JAMA.

[45]  V. Fowler,et al.  Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  F. Fernández‐Avilés,et al.  Clinical course, microbiologic profile, and diagnosis of periannular complications in prosthetic valve endocarditis. , 1999, The American journal of cardiology.

[47]  P E Ochsner,et al.  Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. , 1998, JAMA.